Piramal Pharma Ltd’s Post

This is going to change the way we face audits and build trust, pl join, this is kick off for the game changer in near future which will ensure to reduce stock outs and reduce the frequency of audits depending on the Quality Management Maturity. Let’s come together to embrace and start this for building trust n confidence in our stakeholders and customers 👍

ACG World sets the standard of #global excellence in #pharma #manufacturing    I am thrilled to share that our Capsule factory in Pithampur has been certified by the World Economic Forum as part of its esteemed Global Lighthouse Network (GLN). This accomplishment reflects our continuous commitment to innovation and setting the standard for global excellence in pharmaceutical manufacturing.   6 years ago, as we embarked on our journey toward advance manufacturing, concepts like #AI, #ML, and Industry 4.0 were emerging conversations. Today, the global landscape of innovations has propelled us to fully embrace digitalization, allowing us to reinvent supply chains to deliver better, safer, and more affordable medicines. This success inspires us to consistently elevate standards in quality, efficiency, and sustainable growth. The journey does not end here ; rather it propels us forward, sharing the insights and achievements from this facility across our global operations which will enhance the experience for our partners, regulators, customers, and ultimately, the pharmaceutical ecosystem. Federico Torti, Benjamin Schönfuß How can #India accelerate the adoption of Lighthouse award-winning practices, particularly in the context of the striking 60% representation of Chinese companies, by leveraging its manufacturing excellence and leapfrogging into the #future?

When Product Innovation Goes Awry: Missed Opportunities in Supply Chain Planning When demand exceeds supply, people often innovate their way around the problem to devise a solution that meets the needs of consumers. This is a good thing. Or is it? Non FDA-approved drugs, known as imitation GLP-1s, are now the topic of the day. While underground markets emerge with counterfeit and unregulated versions of these drugs, consumer social media feeds are flooded with unregulated alternatives. While patient safety and protection are essential, real solutions to supply chain availability are needed. ⚠️ In the race to produce and supply these weight-loss and diabetes drugs to a global consumer market, pharmaceutical manufacturers Novo Nordisk and Eli Lilly failed in their product innovation planning efforts. They failed to anticipate the adjacent market needs for their existing products, leaving previously unrealized market demand under-addressed and leaving room for competitors who not only are capturing market share but also put the core brands at risk With Goldman Sachs expecting 15M U.S. adults to be on these medications by 2030, the pressure to expand production capacity is only increasing. The solutions being considered come across as missed opportunities to truly innovate: ✔️ expansion of manufacturing plants to boost production of key ingredient(s) ✔️ acquisition of manufacturing sites to increase production capacity ✔️ increase of production lines within existing sites 💡 Building intelligence into the supply chain planning process is what is needed for sustainable production of these drugs. By reimagining their operating model, pharmaceutical companies can emerge as the industry leaders healthcare needs them to be. Where to start? Map connected processes across the value chain while involving cutting-edge technologies, and people, and incorporate a robust change management practice. 😎 The potential is huge for patient outcomes and market share. How do you bring transformation and change agile practices to your supply chain planning process? Barrett Steele Prasad MK Carrie Longsdorf Mark Dancer Christopher Hurney Rafael M Lopes, MBA, CPHIMS, CPXP Kristin Norton, PhD Jesse King, MA Shara Karasic Linda Chan Curtis Michelson Mark Surkin Mandar Jambotkar #supplychain #productinnovation #innovation #process #planning #customerdemand #consumerexperience #technology #transformation #changeagility #sustainability #imitationdrugs #glp1

Bayer Pharmaceuticals, the renowned German-based pharmaceutical and chemical company credited with the discovery and commercialization of Aspirin, is facing significant challenges. Over the past decade, they have experienced considerable underperformance, resulting in an 80% loss in their market value. Their shares, once trading at a high of €140+, are now hovering around €27-28 per share. Additionally, the company has accumulated a staggering amount of debt, reportedly reaching €34.5 billion. So, what steps are they taking to reverse this downward trend? The new CEO, Bill Anderson, who assumed leadership in June last year, is implementing some bold changes: - He is streamlining several layers of middle management. - He is drastically reducing the extensive 1,362-page corporate handbook. What are his objectives behind these actions? Firstly, by reducing management layers, he aims to achieve annual savings of €2.15 billion. Secondly, by eliminating bureaucracy, he intends to instigate a cultural shift towards trusting and empowering their workforce—individuals with high education, knowledge, expertise, and experience. This cultural shift is expected to foster greater innovation, allowing for quicker decision-making and implementation processes. Under the new structure, Bill Anderson envisions creating between 5,000-6,000 groups or teams working on projects for 90-day cycles before reassessing their progress. These teams will operate independently with minimal oversight. This transformation in culture and structure bears resemblance to the principles outlined in the book 'No Rules Rules' by Reed Hastings and Erin Meyer, which explores the organizational culture of Netflix. Similar strategies have been adopted by tech companies to eliminate layers of bureaucracy, fostering innovation and independence. But will such a model succeed in a highly regulated pharmaceutical environment? There's no reason it shouldn't, as long as close collaboration is maintained between Quality, Regulatory, and all other departments. --------------------------------------------- #bayer #organisationalstructure #corporateculture #reorganisation #biotechnology

🌍🛬 Pharma companies are moving away from globalization and towards a more regional supply chain. With these changing pharma supply chains, new challenges and opportunities arise. This blog article from Logistics Insider discusses the regionalization changes, challenges and opportunities in the pharmaceutical supply chain. #pharma #pharmaceuticals #supplychain #pharmasupplychain #pharmalogistics https://lnkd.in/eei8KjPc

Join our pharma & lifescience series to gain insights on various topics related to the industry! The next session is tomorrow around supply chain

Delve into the future of pharmaceutical logistics with Radovan Simic, SCM - Product Flow & Sustainability Lead at Bayer, at the Global Pharma Supply Chain and Logistics Forum. Radovan will unravel "Demystifying Intelligent Automation – navigating the future with AI-technology and Lean Six Sigma practices," exploring how these innovations drive efficiency, sustainability, and cost-effectiveness across supply chains. Join industry experts and decision-makers to explore the transformative potential of AI and Lean Six Sigma in pharmaceutical logistics. Discover actionable strategies, forge partnerships, and position your organization at the forefront of innovation. Don't miss this opportunity to influence and advance the global pharma supply chain landscape with Bayer and industry leaders. Register now 👇 https://lnkd.in/dn9bsUae For More Info DM at BLX Write Us→ info@brainlinx.com Visit Website→ www.brainlinx.com #brainlinx #innovation #Technology #packaging #sustainability #secondarypackaging #packagingsolutions #innovation #productdesign #Packagingtechnology #primarypackaging #2024events #management #pharmapackaging #conferences2024 #startup #event #supplychain #logistics

🎆 Case Study : Eli Lilly and Company SWOT Analysis: Investing in the Future of Healthcare, One Breakthrough at a Time. SWOT Analysis ✨ 1️⃣ Strengths 🥇 Strong brand reputation: The company's commitment to research, development, and innovation has helped establish its strong brand reputation . Diversified product portfolio: Eli Lilly offers a wide range of products across various therapeutic areas; This diversification helps the company mitigate the risks associated with relying on a single product or market. Robust research and development capabilities: Eli Lilly invests heavily in research and development, allowing the company to continuously innovate and develop new drugs. 2️⃣ Weaknesses ⏳ Dependence on a few key products: While Eli Lilly has a diversified product portfolio, the company still relies heavily on a few key products for a significant portion of its revenue. Limited pipeline: Despite its strong R&D capabilities, Eli Lilly's pipeline of new drugs in late-stage development is relatively limited compared to some of its competitors. Pricing pressures: Pricing pressures are a significant challenge for companies like Eli Lilly. 3️⃣ Opportunities 🤼 Emerging markets: Eli Lilly has the opportunity to expand its presence in emerging markets, such as China, India, and Brazil. Collaborations and partnerships: Strategic alliances can accelerate innovation and enhance the company's competitive advantage. 4️⃣ Threats ☠ Intense competition: The pharmaceutical industry is highly competitive, with numerous players vying for market share. Patent expirations: Many of Eli Lilly's key drugs have patent expirations in the near future, which exposes the company to the risk of generic competition. Adverse events and litigation: Product recalls, safety concerns, or lawsuits related to side effects can damage the company's reputation, result in financial losses, and impact customer trust.#SWOTanalysis #businessstrategy #pharmaceuticalindustry #healthcare #lifesciences #elililly #competitiveanalysis #marketleader #strongbrands #researchanddevelopment #globalreach

In this Life Science Leader article, industry experts share positive and negative forecasts for the upcoming year, addressing concerns such as supply chain issues and advantages including emerging technologies that potentially will propel the industry forward. Omair Ahmed, Chief Operating Officer of Nexus Pharmaceuticals (the recipient of Honorable Mention 2023 FOYA), elaborates on the proactive measures Nexus is presently undertaking to address potential future drug shortages. Read More: https://bit.ly/3RaLYve #DrugManufacturing #Pharma #FOYA24

Biopharma manufacturing costs have risen steadily over the past few years, and there’s no end in sight. The pandemic, geopolitical events, and trade barriers have exposed the fragility of global supply chains, and new treatment modalities have driven up manufacturing unit costs - with unforeseen consequences for the industry. Faced with systems-level challenges, what can biopharma companies do to proactively manage their costs while remaining competitive? In this recent article for @Boston Consulting Group (BCG), @Wim Celen, @Gian Carlo Walker, @Surbhi Jain, and @Arya Taupin Karabulut offer insights into how leaders can manage their costs of goods sold while optimizing their manufacturing networks, building resilient supply chains, and managing their portfolios and pipelines. This piece does a great job of articulating digestible and practical steps for leaders: https://lnkd.in/d3xjeKiw